Clinical trials recruiting in Tbilisi, Georgia

Phase breakdown

Conditions recruiting in Tbilisi, Georgia

Recruiting trials in Tbilisi, Georgia

• A Clinical Study of MK-1045 in People With Lupus or Rheumatoid Arthritis (MK-1045-004)
  NCT07363590 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
  NCT06868277 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
  NCT07184944 · Phase: Phase 3 · Ages: 16 Years to 80 Years · Sex: All (male and female)
• A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
  NCT07185009 · Phase: Phase 3 · Ages: 16 Years to 80 Years · Sex: All (male and female)
• A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study With an Open-Label Extension Evaluating the Efficacy and Safety of VENT-03 in Adult Participants With Active Cutaneous Lupus Erythematosus With or Without Systemic Lupus Erythematosus
  NCT07260877 · Phase: Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female)
• A Phase 1b Open-label Study to Evaluate Safety of Plamotamab in Participants With Rheumatoid Arthritis
  NCT07230353 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female)
• A Phase 1b Study of Budoprutug in Systemic Lupus Erythematosus (SLE)
  NCT07011043 · Phase: Phase 1 · Ages: 18 Years to 65 Years · Sex: All (male and female)
• A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
  NCT06226883 · Phase: Phase 2 · Ages: 18 Years to 85 Years · Sex: All (male and female)
• A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease
  NCT07113522 · Phase: Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female)
• A Phase 3 Study of Efepoetin Alfa for Treatment of Anemia in Patients With Chronic Kidney Disease on Dialysis
  NCT06466785 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Phase I Dose Escalation and Dose Expansion Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Durvalumab
  NCT07391670 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female)
• A Platform Study in Non-Small Cell Lung Cancer (NSCLC)
  NCT06996782 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
  NCT06318169 · Phase: Phase 3 · Ages: 18 Years to 80 Years · Sex: All (male and female)
• A Study of BBT002 in Healthy Volunteers (HVs) and in Adult Patients With Chronic Obstructive Pulmonary Disease (COPD) or Chronic Rhiosininusitis With Nasal Polyps (CRSwNP)
  NCT06944925 · Phase: Phase 1 · Ages: 18 Years to 80 Years · Sex: All (male and female)
• A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus Erythematosus
  NCT06613360 · Phase: Phase 1 · Ages: 18 Years to 70 Years · Sex: All (male and female)
• A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
  NCT06345729 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
  NCT05774951 · Phase: Phase 3 · Ages: 18 Years to 130 Years · Sex: All (male and female)
• A Study of EPX-100 (Clemizole Hydrochloride) in Participants With Dravet Syndrome
  NCT04462770 · Phase: Phase 3 · Ages: 2 Years and older · Sex: All (male and female)
• A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
  NCT06492616 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis
  NCT07012395 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections
  NCT06056297 · Phase: Phase 3 · Ages: 12 Years and older · Sex: All (male and female)
• A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus
  NCT07438496 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis
  NCT07067463 · Phase: Phase 3 · Ages: 18 Years to 60 Years · Sex: All (male and female)
• A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis
  NCT07299019 · Phase: Phase 3 · Ages: 18 Years to 60 Years · Sex: All (male and female)
• A Study to Assess the Safety and Tolerability of SR-878 in Patients With Rheumatoid Arthritis
  NCT07433335 · Phase: Phase 1 · Ages: 18 Years to 60 Years · Sex: All (male and female)
• A Study to Compare Efficacy, Pharmacokinetics, Safety and Immunogenicity of MB04 [proposed Etanercept Biosimilar] to Enbrel® [EU-sourced] in Rheumatoid Arthritis
  NCT06596772 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• A Study to Evaluate IPN10200 Safety and Efficacy in the Prevention of Episodic or Chronic Migraine in Adults
  NCT06625060 · Phase: Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female)
• A Study to Evaluate Pharmacokinetics (PK) and Safety of Subcutaneous (SC) Ublituximab Administered at Various Injection Sites and Relative Bioavailability Via Autoinjector (AI) Versus Syringe Subcutaneously in Participants With Multiple Sclerosis (MS)
  NCT07503873 · Phase: Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female)
• A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
  NCT06419374 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
  NCT06430801 · Phase: Phase 3 · Ages: 16 Years to 80 Years · Sex: All (male and female)
• A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Crohn's Disease.
  NCT06637631 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Ulcerative Colitis
  NCT06867094 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• A Study to Investigate the Efficacy and Safety of Two Different Doses of Twice Daily Distal Jejunal-release Dextrose Beads Formulations Combined With a Gel Composition Compared to Placebos in Obese Subjects With Weight Related Comorbidities
  NCT07008456 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
  NCT06219941 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• Ablation of Arteries for the Treatment of Type 2 Diabetes Mellitus and Its Comorbidities
  NCT05369065 · Phase: Phase 1 · Ages: 21 Years to 65 Years · Sex: All (male and female)
• Alleviant ALLAY-HF Study
  NCT05685303 · Phase: Not applicable (e.g. observational or device study) · Ages: 40 Years and older · Sex: All (male and female)
• Alleviant ALLAY-HFrEF Study
  NCT06812533 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female)
• An Evaluation of NGM120 in a Randomized, Double-blind, Placebo-controlled Study in Participants With Colorectal Cancer Who Have Cancer Cachexia.
  NCT07033026 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
  NCT07184931 · Phase: Phase 3 · Ages: 16 Years to 80 Years · Sex: All (male and female)
• An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
  NCT07184996 · Phase: Phase 3 · Ages: 16 Years to 80 Years · Sex: All (male and female)
• BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01)
  NCT07625644 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Carotid Implants for PreveNtion of STrokE ReCurrEnce From Large Vessel Occlusion in Atrial Fibrillation Patients Treated With Oral Anticoagulation
  NCT05723926 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female)
• ColoSeal™ ICD System Safety and Feasibility Study
  NCT06402188 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 70 Years · Sex: All (male and female)
• Confirmatory Clinical Study in Active Ulcerative Colitis
  NCT07296315 · Phase: Phase 2 · Ages: 16 Years and older · Sex: All (male and female)
• ContraBand™: Safety & Feasibility Study (RM-20-01)
  NCT05230745 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 85 Years · Sex: All (male and female)
• Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
  NCT07179380 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
  NCT07190209 · Phase: Phase 3 · Ages: 40 Years to 80 Years · Sex: All (male and female)
• Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response
  NCT06641089 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)
  NCT06651281 · Phase: Phase 3 · Ages: No age limits stated · Sex: All (male and female)
• Feasibility Study of the Supira System in Patients Undergoing HRPCI With Support Beyond the PCI Procedure
  NCT07407816 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 90 Years · Sex: All (male and female)
• First-in-human, Study of MATTISSE® Tissue Engineering Chamber in Adult Female Patients Undergoing Breast Reconstruction After Mastectomy for Cancer
  NCT05460780 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: Female
• LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
  NCT06632457 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
  NCT06632444 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Long-term Safety and Efficacy of a Modified Suprachoroidal Silicone Tube (SST) Shunt
  NCT06691555 · Phase: Not specified · Ages: 40 Years to 90 Years · Sex: All (male and female)
• Low Dead-space Injecting Equipment Distribution Program for People Who Inject Drugs in Low- and Middle-income Countries
  NCT06395129 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female)
• Magenta Elevate™ Clinical Feasibility Study in Cardiogenic Shock
  NCT07293923 · Phase: Not applicable (e.g. observational or device study) · Ages: 40 Years to 89 Years · Sex: All (male and female)
• PRIDE III Prison Interventions and HIV Prevention Collaboration
  NCT06962033 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female)
• Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
  NCT04613596 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)
  NCT06095583 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• REGN7508 in Adult Participants for Prevention of Cancer-Associated Thrombosis
  NCT07410117 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
  NCT07173751 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Reduction of Mitral Regurgitation With the SATURN Trans-Septal Transcatheter Mitral Valve Replacement (TMVR) System in Patients With Severe Symptomatic Mitral Regurgitation
  NCT06414265 · Phase: Not applicable (e.g. observational or device study) · Ages: 65 Years and older · Sex: All (male and female)
• Reprieve System Pilot Study
  NCT06272734 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female)
• Safety and Performance of ENDOMATIC SEPIOLA Left Atrial Appendage (LAA) Closure Device
  NCT06099106 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female)
• Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
  NCT06712316 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Study of GS-0151 in Participants With Rheumatoid Arthritis
  NCT06902519 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• Study of LFD-200 in Healthy Adults and Adults With Moderate to Severe Rheumatoid Arthritis
  NCT07207954 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers
  NCT05098132 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• Study of XmAb942 in Healthy Participants and Participants With Ulcerative Colitis
  NCT06619990 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• Synchronized Diaphragmatic Stimulation in Symptomatic Heart Failure
  NCT06552637 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female)
• The Safety and Feasibility of the eLym™ System
  NCT05747196 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female)
• V-Lap System For Wirelessly Measuring And Monitoring Left Atrial Pressure (LAP) In Patients With Advance CHF
  NCT05712824 · Phase: Not applicable (e.g. observational or device study) · Ages: 22 Years to 88 Years · Sex: All (male and female)
• iCaReMe Global Registry: Multinational Real-world Evidence in Cardiorenal and Metabolic Diseases
  NCT03549754 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female)

Common questions

How many clinical trials are recruiting in Tbilisi, Georgia?

73 recruiting trials have at least one study site in Tbilisi, Georgia.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.